PALI – palisade bio, inc. (US:NASDAQ)
Stock Stats
News
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
Palisade Bio (NASDAQ:PALI) is now covered by analysts at B. Riley. They set a "buy" rating on the stock.
Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108 [Yahoo! Finance]
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108
Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Wall Street Zen
Form 4 PALISADE BIO, INC. For: Jan 09 Filed by: Williams Donald Allen
Form SCHEDULE 13G PALISADE BIO, INC. Filed by: JANUS HENDERSON GROUP PLC
Form 8-K PALISADE BIO, INC. For: Dec 03
Form S-8 PALISADE BIO, INC.
Form 10-Q PALISADE BIO, INC. For: Sep 30
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.